Table 2.
Anticoagulation by Medicaid Status in the ORBIT‐AF Population*
| Overall (N=10 133) | Non‐Medicaid (N=9663) | Medicaid (N=470) | P Valuea | Unadjusted ORb (95% CI) | Adjusted ORb (95% CI) | P Value | |
|---|---|---|---|---|---|---|---|
| OAC use | |||||||
| OAC at baseline | 76.1 | 76.3 | 72.8 | 0.08 | 0.80 (0.60, 1.07) | 0.82 (0.61, 1.09) | 0.17 |
| OAC (any follow‐up visit) | 82.0 | 82.2 | 79.6 | 0.16 | 0.93 (0.77, 1.13) | 0.99 (0.80, 1.23) | 0.92 |
| OAC at baseline among CHADS2 ≥2 | 80.1 | 80.5 | 73.2 | <0.001 | 0.65 (0.47, 0.89) | 0.68 (0.49, 0.94) | 0.02 |
| OAC at baseline among CHADS2‐VASc ≥2 | 78.1 | 78.3 | 73.7 | 0.02 | 0.74 (0.54, 1.01) | 0.77 (0.57, 1.04) | 0.09 |
| NOAC use | |||||||
| NOAC at baseline or any follow‐up visit | 16.1 | 16.3 | 12.1 | 0.02 | 0.87 (0.65, 1.17) | 0.96 (0.69, 1.32) | 0.80 |
| NOAC among CHADS2 ≥2 | 13.9 | 14.1 | 10.8 | 0.07 | 0.91 (0.64, 1.30) | 0.92 (0.63, 1.33) | 0.65 |
| NOAC among CHADS2‐VASc ≥2 | 15.5 | 15.6 | 11.9 | 0.03 | 0.90 (0.66, 1.23) | 0.97 (0.70, 1.36) | 0.87 |
| TTRc | 68 (54–79) | 60 (45–73.5) | −6.58 (−9.61, −3.54) | −2.93 (−5.67, −0.19) | 0.04 | ||
IQR indicates interquartile range; NOAC, novel oral anticoagulant; OAC, oral anticoagulation; ORBIT‐AF, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation; TIA, transient ischemic attack; TTR, time in therapeutic range.
Estimates are percentages unless otherwise indicated.
Chi‐squared tests.
Generalized estimating equations logistic regression models. Adjusted models included age, race, sex, smoking, cancer, hypertension, osteoporosis/hip fracture, diabetes, hypothyroidism, gastrointestinal bleed, obstructive sleep apnea, insufficient kidney function, hyperlipidemia, anemia, cognitive impairment/dementia, frailty, coronary artery disease, chronic obstructive pulmonary disease, alcohol or drug abuse, peripheral vascular disease, sinus node dysfunction, stroke/transient ischemic attack, congestive heart failure, valvular disease, heart rate, blood pressure, body mass index, left atrial diameter, type of atrial fibrillation (AF), past cardioversions, past antiarrhythmic drugs, past AF interventional therapy, and functional status.
Calculated from the Rosendaal method and based on patients who were taking warfarin at baseline and had at least 5 international normalized ratio measurements during follow‐up (n=5322). Estimates shown are from linear regression.